AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Juan José Davidovich, general manager of the Italian ophthalmology leader Sifi, speaks about the importance of Mexico as a base to enter Latin America and sets the goal of prospering…
Alfa Wassermann is a pharmaceutical group with an Italian heart and an international outlook. The general manager for Mexico discusses the competitive advantages Mexico offered to start operations in Latin…
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
Since he took office in December 2012, President Enrique Peña Nieto has achieved much in terms of the number of major reforms passed in Mexico. Besides the most expected change…
During 2013 Mundipharma entered Brazil, Mexico and Colombia to consolidate its presence in the Latin American region. The general director for Mexico discusses the company’s plans to become leader in…
UCB has transformed into a specialty care pharma which focuses on bringing solutions to patients suffering from severe chronic diseases. The vice president and region head for Americas discusses how…
Mexico is one of GSK’s growth engines in Latin America. The VP and general manager for Mexico discusses how the country is increasingly playing a strategic role for the company…
Aspen Labs wants Latin America to be the third pillar of success for the company, and is doing it in a different way. The CEO for Spanish Latin America discusses…
Indian companies are increasingly interested in tapping into the alluring Mexican and Latin American pharmaceutical markets. The general manager of the API and drug producer discusses the vision behind the…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
The executive director and general manager of Amgen Mexico discusses how the company relies on Mexico as a hub for clinical research, with an investment of over USD 22 million…
Recognized by the University of Pennsylvania as one of the top 30 think tanks in the world for health policy, FUNSALUD is committed to propose solutions to Mexico’s most important…
See our Cookie Privacy Policy Here